CN107353286A - Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application - Google Patents
Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application Download PDFInfo
- Publication number
- CN107353286A CN107353286A CN201610304561.XA CN201610304561A CN107353286A CN 107353286 A CN107353286 A CN 107353286A CN 201610304561 A CN201610304561 A CN 201610304561A CN 107353286 A CN107353286 A CN 107353286A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- nitrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of imidazo [1,2 b] pyridazine amide-type Bcr Abl kinase inhibitors and its preparation method and application, the general structure of the inhibitor is shown in formula I.It is used to prepare the medicine of prevention and/or treatment and protein kinase activity exception relevant disease, the method particularly with the medicine of Bcr Abl protein kinase activity exception relevant diseases present invention also offers the pharmaceutically acceptable salt of the compound comprising Formulas I, composition and using the salt, composition.
Description
Technical field
The present invention provides a kind of novel imidazole simultaneously [1,2-b] pyridazine amide compound, or such compound can pharmaceutically connect
The salt received, its preparation method, its pharmaceutical composition, and it is used to prepare prevention and/or treatment and protein kinase activity is abnormal
The medicine of relevant disease, the method particularly with the medicine of Bcr-Abl protein kinase activity exception relevant diseases.
Background technology
Protein kinase is that the phosphate group on ATP is transferred on protein into specific serine, threonine or tyrosine
Enzyme on residue.The phosphorylation of protein causes the activation of signal transduction path, and key has been played to internal complicated bioprocess
Effect, including cell growth, metabolism, differentiation and death.It is abnormal as caused by abnormal or unsuitable protein kinase activity
It is relevant with many diseases known to signal, including cancer, inflammation, autoimmune disease, metabolic disease, infection, nervous centralis
Systemic disease and angiocardiopathy etc..Therefore, protein kinase be drug development in recent years popular target spot (Cohen,
Nat.Rev.Drug Discovery 2002,1,309)。
The bcr gene phase reciprocity of c-abl genes and No. 22 chromosome long arm distal end on human body Chromosome 9
Position, generates two fusions:Bcr-Abl genes on 22q- chromosomes and the Abl-Bcr bases on 9q+ chromosomes
Cause.Bcr-Abl genes are Philadelphia chromosomes, and it expresses 210kD protein (p210Bcr-Abl).Bcr-Abl protein
EGFR-TK of the Abl parts containing Abl, it is tightly adjusted in the c-abl of prototype, but merges egg in Bcr-Abl
Continuously activated in white matter, so as to cause the out of control of cell growth.Bcr-Abl is present in 95% CML patient, and
In the patient of 10-25% ALLs (ALL).Imatinib (Imatinib) is a kind of Bcr-Abl tyrosine
The inhibitor of kinases, and clinic is proved to be a kind of effective preparation (Druker et for treating CML
al.N.Engl.J.Med.2006,355,2408).However, although continue treatment with imatinib, some CML patients late or
The blast phase of crisis can recur, and reason is to produce the resistance to the action of a drug to medicine.Drug-fast molecular basis is Bcr-Abl kinases knot
There is the variant to Imatinib resistance in structure region.At present, second generation Bcr-Abl kinase inhibitors have listed, and mainly have and reach
Sand replaces Buddhist nun (dasatinib), AMN107 (nilotinib), bosutinib (bosutinib) and Ponatinib
(ponatinib).Although these medicines can show encouraging effect initial stage in listing, some researchers report it
Will trigger new mutation after use in Bcr-Abl kinases area.Therefore, the Bcr-Abl kinases for mutant of renewal is developed
Inhibitor seems necessary.
The content of the invention
The present invention provides a kind of imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors, and it is with following logical
Compound or its pharmaceutically acceptable salt shown in Formulas I:
In above-mentioned formula I:
(a)R1It is independent hydrogen, or methyl;R2It is any substituted n membered cyclic alkyls, wherein n=3-11, and on ring
Including at most n-1 hetero atom, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus, or
(b)R1And R2Connection forms a m member azepine cyclic hydrocarbon radical arbitrarily substituted, wherein m=3-11, and includes on ring
At most m-2 other hetero atoms, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as described in formula I, and described can pharmaceutically connect
The salt received includes but is not limited to hydrochloride, phosphate, sulfate, acetate, trifluoroacetate, maleate, benzene sulfonate, first
Base benzene sulfonate, fumarate, tartrate etc..
The present invention provides a kind of Pharmaceutical composition, and it includes the compound as described in formula I of unit dose, a kind of pharmacy
Upper acceptable carrier and excipient, and optional other Bcr-Abl kinase activations mediation treatment for diseases agent.
The present invention provides the pro-drug of the compound as described in formula I.
Compound or its pharmaceutically acceptable salt of the present invention offer as described in formula I are preparing prevention and/or treatment
Application in the disorder agent mediated by Bcr-Abl kinase activations.The Bcr-Abl kinase activations mediation illness can be propagation
Property disease.The proliferative diseases specifically may be selected from:Solid tumor, sarcoma, CML, chronic myelocytic leukemia, gastrointestinal stromal tumor
(GIST), acute myeloblastic leukemia (ALL), thyroid cancer, stomach cancer, the carcinoma of the rectum, Huppert's disease, neoplasia and other
Hypertrophic or proliferative diseases or its combination.
In specific embodiments:
The present invention provides compound or its pharmaceutically acceptable salt as shown in formula I, wherein (a) R1
It is independent hydrogen, or methyl;R2It is any substituted n membered cyclic alkyls, wherein n=3-11, and include at most on ring
N-1 hetero atom, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (a) R1It is independent
Hydrogen, or methyl;R2It is any substituted n member cycloalkyl, wherein n=3-11, and include at most n-1 hetero atom on ring,
These hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (a) R1It is independent
Hydrogen, or methyl;R2It is any substituted n member cycloalkyl, wherein n=6-11, and include at least one nitrogen-atoms on ring, and
At most n-2 hetero atom, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (a) R1It is independent
Hydrogen, or methyl;R2It is any substituted n member azacycloalkyls, wherein n=6-11, and ring substituents are selected from methyl, halogen
Plain substituent, hydroxyl and amino.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (a) R1It is independent
Hydrogen, or methyl;R2It is methyl substituted n members azacycloalkyl, wherein n=6-11.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in claim 1, wherein (a) R1It is independent
Hydrogen, or methyl;R2Selected from following radicals:
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (b) R1And R2Connect shape
Into the m arbitrarily substituted a member azepine cyclic hydrocarbon radical, wherein m=3-11, and include at most m-2 other hetero atoms on ring,
These hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (b) R1And R2Connect shape
Into the m arbitrarily substituted a member azacycloalkyl, wherein m=3-11, and include at most m-2 other hetero atoms on ring,
These hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (b) R1And R2Connect shape
Into the m arbitrarily substituted a member azacycloalkyl, wherein m=5-7, and include at most m-2 other hetero atoms on ring, this
A little hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (b) R1And R2Connect shape
Into the m arbitrarily substituted a member azacycloalkyl, wherein m=5-7, and include 0-1 other nitrogen-atoms on ring.
The present invention provides the compound or its pharmaceutically acceptable salt as shown in formula I, wherein (b) R1And R2Connect shape
Into the m arbitrarily substituted a member azacycloalkyl, wherein m=5-7, include 0-1 other nitrogen-atoms, and substituent on ring
Selected from methyl, halogenic substituent, hydroxyl and amino.
The present invention provides the compound as shown in formula I, and its structural formula is selected from following table:
The present invention provides the compound as shown in formula I, its structural formula such as P16:
The present invention provides the compound as shown in formula I, its structural formula such as P17:
Compared with prior art, the invention has the advantages that:
Imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors provided by the invention, it is that new having resists
The compound of Bcr-Abl kinase activities, there is good inhibitory activity to Bcr-Abl kinases in vitro.Bcr-Abl kinases is thin
Played a significant role in born of the same parents' signal transduction and conversion, it is by phosphorylation and activates a series of stream substrates, promotes CML maturation grains
Cell infinite multiplication.Bcr-Abl is not expressed in normal cell, is the ideal targets for treating CML.Bcr-Abl inhibitor passes through
Suppress the purpose that Bcr-Abl kinase activities can reach treatment CML.Result of the test shows the imidazo [1,2- prepared by the present invention
B] pyridazine amide-type Bcr-Abl kinase inhibitors can effectively suppress Bcr-Abl activity and suppress the growth of tumour cell
And propagation.Illustrate that such imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors can be used for preparing Bcr-Abl suppression
Agent medicine and antineoplastic.
The preparation method of imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors provided by the invention, there is original
The advantages of material is easy to get, and reaction condition is gentle, and course of reaction is simple to operate, and agents useful for same is cheap.
Embodiment
The exemplary of the present invention is described more fully below.However, these embodiments are only for illustration purpose, and
It is not intended to limitation the scope of the present invention.
Definition
Following term used herein and expression are with the implication specified.
" pharmaceutically acceptable salt " refers to the form for the basic group in parent compound being converted into salt.Pharmaceutically may be used
The salt of receiving is include but not limited to, the inorganic or organic acid salt of basic group such as amine (ammonia) base.The present invention pharmaceutically may be used
The salt of receiving can be synthesized by parent compound, i.e., the acid of the basic group in parent compound and 1-4 equivalents is in a solvent
Reacted in system.
Present invention additionally comprises the prodrug of the compound.Prodrug is a pharmacological agents (medicine), is derived by parent drug
Out.Once entering in vivo, prodrug, which is just metabolized, is transformed into parent drug.Prodrug can pass through the one or more to parent drug
Functional group is substituted and prepared, and its substituted radical will be degraded and discharge parent compound in vivo.
Specifically, protein kinase of the present invention also includes the kinases of mutation, and the Abl and Bcr-Abl of such as mutation swash
Enzyme.Abl the and Bcr-Abl kinases of mutation includes, and has one or more following mutant:G250E、E255V、T315I、
F317L and M351T etc..
" IC50 " refers to the number that specific test compound produces 50% maximum suppression effect in the experiment for testing the effect
Amount, concentration or dosage.
Preparation method
The compound of the present invention can be prepared by known chemical reaction and step.Some have been shown below and has synthesized this hair
The representational method of bright compound.It is well known that the property of the substituent needed for desired target compound often determines
The method for optimizing of synthesis.
Another aspect of the present invention is related to the preparation method of compound of Formula I.The compound of the present invention can use following
The step of and method prepare.
General steps
The compound prepared in the embodiment of the present invention can use scheme 1 or the two schemes of scheme 2.Compared compared with scheme 2, side
Case 1 needs to participate in reaction with the intermediate (SM4) with protection group (PG), can be obtained in the final step deprotection base of synthesis
To target compound.
Scheme 1
Scheme two
The compound of this patent protection can be synthesized using this synthetic route.The iodo- methyl 4 methylbenzoates of 3- (SM1) with
Trimethyl silicane ethyl-acetylene occurs Sonogashira coupling reactions under the catalysis of bi triphenyl phosphorus palladium chloride and obtains intermediate 1.It is right
Intermediate 1 implements de- trimethyl silicon-based protecting group and obtains intermediate 2.Imidazo [1,2-b] pyridazine (SM2) and N- iodo succinyl
Imines heats in DMF and obtains iodo intermediate 3.Intermediate 2 reacts in DMF with intermediate 3, with palladium catalyst, such as four (three
Phenylphosphine) palladium, so as to obtain intermediate 4.Intermediate 4 is in methanol and tetrahydrofuran in the mixed solvent alkali such as lithium hydrate
Obtain intermediate 5.2- fluoro-5-nitro trifluor toluenes (SM3) are with SM4 or SM5 in the basic conditions if potassium carbonate is in a kind of solvent
Reaction obtains nitro compound intermediate 6 or 8 in system such as acetonitrile.By the nitro on intermediate 6 or 8 in a kind of solvent such as first
Reacted in alcohol with hydrogen, make catalyst with palladium carbon, obtain intermediate 7 or 9.Intermediate 5 and intermediate 7 or 9 use one kind in DMF
Condensation reaction occurs for condensing agent such as EDCI, obtains target compound or further slough protection group in acid condition obtaining target
Compound P1-P19.
Embodiment 1
4- methyl -3- ((trimethyl silicon substrate) acetenyl) methyl benzoate
The iodo- methyl 4 methylbenzoates of 3- (SM1) (30g, 0.471mol) are dissolved in tetrahydrofuran (1200mL).Add
Enter trimethyl silicane ethyl-acetylene (92.3g, 0.942mol) and diisopropyl ethyl amine (72.9g, 0.565mol).System vacuumizes,
Then inflated with nitrogen.Add cuprous iodide (8.92g, 0.047mol) and bi triphenyl phosphorus palladium chloride (16.5g, 0.024mol).
System vacuumizes, then inflated with nitrogen.Stirred 4 hours in 80 DEG C under nitrogen atmosphere, after being cooled to room temperature, the mixture uses diatom
Soil filtering, diatomite are thoroughly washed with ethyl acetate.Filtrate uses water and saturated common salt water washing successively, and sodium sulphate is dried, filtering
Be concentrated to dryness.Crude by column chromatography purifies (ethyl acetate/petroleum ether=1:50), obtain title compound (95.1g,
82.6%) it is brown solid.LC-MS (m/z)=247.6 [M+H]+.1H NMR(400MHz,CDCl3)δ8.19(s,1H),
7.86 (d, J=8.4Hz, 1H), 7.30 (d, J=8.4Hz, 1H), 3.41 (s, 3H), 2.32 (s, 3H), 0.11 (s, 9H).
3- acetenyl methyl 4 methylbenzoates
By 4- methyl -3- ((trimethyl silicon substrate) acetenyl) methyl benzoates (95g, 0.386mol) and potassium fluoride
(67.2g, 1.158mol) stirring is dissolved in 1000mL methanol, is stirred overnight at room temperature.It is concentrated to dryness, crude product purifies (second through column chromatography
Acetoacetic ester/petroleum ether=1:50) it is yellow solid, to obtain title compound (51g, 76.1%).LC-MS (m/z)=175.2 [M
+H]+.1H NMR (400MHz, CDCl3) δ 8.29 (s, 1H), 7.82 (d, J=8.4Hz, 1H), 7.34 (d, J=8.4Hz, 1H),
4.15(s,1H),3.85(s,3H),2.41(s,3H)。
3- iodine imidazo [1,2-b] pyridazine
By imidazo [1,2-b] pyridazine (40g, 0.336mol), N- N-iodosuccinimides (90g, 0.402mol) are dissolved in
DMF (500mL), displacement nitrogen 3 times.By mixture, 80 DEG C are heated 3 hours, add a collection of N- iodos in addition
Succimide (45g, 0.201mol), continue to heat 4 hours at 80 DEG C.Cooling, water (250mL) is poured into by reactant mixture
In, and extracted with dichloromethane (2 × 150mL).Organic phase is collected, Na2SO4 is dried, filtered, is concentrated to dryness.Crude product is through post layer
Analysis purifying (ethyl acetate/petroleum ether=1:10) it is brown solid, to obtain title compound (45g, 54.9%).LC-MS (m/z)=
246.1[M+H]+.1H NMR (400MHz, CDCl3) δ 8.46 (d, J=4.4Hz, 1H), 7.92 (d, J=9.2Hz, 1H), 7.85
(s, 1H), 7.08 (dd, J=4.4,9.2Hz, 1H).
3- (imidazo [1,2-b] pyridazine -3- acetenyls)-methyl 4 methylbenzoate
3- iodine imidazo [1,2-b] pyridazine (10g, 0.041mol), 3- acetenyl 4- methylbenzene first are added into 100mL bottles
Sour methyl esters (7.14g, 0.041mol), tetrakis triphenylphosphine palladium (1.42g, 0.0021mol), cuprous iodide (0.778g,
0.0041mol), diisopropyl ethyl amine (6.35g, 0.049mol) and N ' dinethylformamides (50mL).Mixture is put
Change nitrogen and heat 80 DEG C afterwards three times and stir 4 hours, then cool down, reactant mixture is poured into water (150mL), and with acetic acid second
Ester (3 × 100mL) extracts.Organic phase is collected, Na2SO4 is dried, filtered and be concentrated to dryness.Crude product purifies (acetic acid through column chromatography
Ethyl ester/petroleum ether=1:5) it is white solid, to obtain title compound (10g, 84.7%).LC-MS (m/z)=292.6 [M+H]+.
1H NMR (400MHz, CDCl3) δ 8.76 (d, J=3.2Hz, 1H), 8.29 (s, 1H), 7.98 (dd, J=3.2Hz, 9.2Hz,
1H), 7.90 (d, J=8.4Hz, 1H), 7.85 (s, 1H), 7.34 (d, J=8.4Hz, 1H), 7.22 (d, J=9.2Hz, 1H),
3.86(s,3H),2.35(s,3H)。
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl benzoic acids
3- (imidazo [1,2-b] pyridazine -3- acetenyls)-methyl 4 methylbenzoate (10g, 0.034mol) is dissolved in four
Hydrogen furans/methanol/water (2:2:Lithium hydroxide (3.3g, 0.137mol) 1,200mL) is added afterwards.Reaction system is stirred at room temperature
Overnight.After reaction terminates, system removes organic solvent under reduced pressure, and gains are adjusted to pH 5~6 with 6N hydrochloric acid solutions.In system
The white precipitate of generation is filtered, and it is faint yellow solid to obtain title compound (9g, 94.6%) after washing, drying.LC-MS(m/
Z)=276.1 [M-H]-.1H NMR (400MHz, CDCl3) δ 11.03 (s, 1H), 8.76-8.75 (d, J=3.2Hz, 1H),
8.45 (s, 1H), 8.07-8.05 (d, J=8.4Hz, 1H), 7.97-7.94 (dd, J1=3.2Hz, J2=9.2Hz, 1H), 7.85
(s, 1H), 7.44-7.42 (d, J=8.4Hz, 1H), 7.23-7.20 (d, J=9.2Hz, 1H), 2.47 (s, 3H).
(R)-(1- (4- nitros -2- (trifluoromethyl) phenyl) pyrrolidin-3-yl) t-butyl carbamate
By fluoro- 4- nitros -2- (trifluoromethyl) benzene (2g, 9.57mmol) of 1-, R) -3- t-butoxycarbonyl amino pyrrolidines
(1.9g, 10.5mmol) is dissolved in acetonitrile (30mL) and adds potassium carbonate (2.9g, 21.1mmol) afterwards.Reaction system stirs at 80 DEG C
Overnight, then cool down, reactant mixture is poured into water (20mL), and extracted with ethyl acetate (3 × 20mL).Collect organic
Phase, Na2SO4 are dried, are filtered and be concentrated to dryness.Crude product purifies (ethyl acetate/petroleum ether=1 through column chromatography:5), obtain titled
Compound (2.7g, 74%) is white solid.LC-MS (m/z)=376.4 [M+H]+.
(R)-(1- (4- amino -2- (trifluoromethyl) phenyl) pyrrolidin-3-yl) t-butyl carbamate
By (R)-(1- (4- nitros -2- (trifluoromethyl) phenyl) pyrrolidin-3-yl) t-butyl carbamate (2.0g,
5.3mmol) it is dissolved in methanol (40mL) and adds Pd/C (10%, 200mg) afterwards.System vacuumizes, and is then flushed with hydrogen gas.In hydrogen balloon atmosphere
It is stirred at room temperature under enclosing overnight, mixture is filtered with diatomite, and diatomite is thoroughly washed with methanol.The thick production of gained after filtrate concentration
Thing purifies (ethyl acetate/petroleum ether=1 through column chromatography:1) it is white solid, to obtain title compound (1.7g, 91%).LC-
MS (m/z)=346.4 [M+H]+.
(R)-N- (4- (3- amino-pyrrolidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -
3- acetenyls) -4- methyl benzamides
Into 20mL single port bottles add 3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl benzoic acids (100mg,
0.36mmol), (R)-(1- (4- amino -2- (trifluoromethyl) phenyl) pyrrolidin-3-yl) t-butyl carbamate (125mg,
0.36mmol), 1- ethyls-(3- dimethylaminopropyls) phosphinylidyne diimmonium salt hydrochlorate (104mg, 0.54mmol), 4- diformazan ammonia
Yl pyridines (66mg, 0.54mmol), N ' dinethylformamides (5mL).Mixture displacement nitrogen is heated into 50 DEG C afterwards three times to stir
Mix 3 hours, then cool down, reactant mixture is poured into water (10mL), and extracted with dichloromethane (3 × 10mL).Collection has
Machine phase, Na2SO4 are dried, are filtered and be concentrated to dryness.Crude product is dissolved in trifluoroacetic acid (0.5mL) dichloromethane (5mL) solution, room
Temperature reaction 2 hours.Reactant mixture is concentrated, with ethanol/methylene recrystallize title compound trifluoroacetate
(113mg, 43%) is white solid.LC-MS (m/z)=505.6 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.42
(s, 1H), 8.74 (dd, J=1.6,4.4Hz, 1H), 8.28 (dd, J=1.6,9.2Hz, 1H), 8.24 (s, 1H), 8.21 (d, J
=1.6Hz, 1H), 8.13 (d, J=2.4Hz, 1H), 8.00 (dd, J=2.4,9.2Hz, 1H), 7.96 (dd, J=1.6,
7.6Hz, 1H), 7.56 (d, J=8.4Hz, 1H), 7.42 (q, J=4.4Hz, 1H), 7.29 (d, J=8.4Hz, 1H), 3.51-
3.45(m,2H),3.27-3.22(m,2H),3.15-3.11(m,1H),2.55(s,3H),2.51-2.33(m,2H)。
Example 2 below -10 is all prepared according to the method for scheme 1 and embodiment 1.
Embodiment 2
(S)-N- (4- (3- amino-pyrrolidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -
3- acetenyls) -4- methyl benzamides
LC-MS (m/z)=505.1 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.42(s,1H),8.74(dd,J
=1.6,4.4Hz, 1H), 8.28 (dd, J=1.6,9.2Hz, 1H), 8.24 (s, 1H), 8.21 (d, J=1.6Hz, 1H), 8.13
(d, J=2.4Hz, 1H), 8.00 (dd, J=2.4,9.2Hz, 1H), 7.96 (dd, J=1.6,7.6Hz, 1H), 7.56 (d, J=
8.4Hz, 1H), 7.42 (q, J=4.4Hz, 1H), 7.29 (d, J=8.4Hz, 1H), 3.70-3.77 (m, 2H), 3.51-3.45
(m, 2H), 3.27-3.22 (m, 2H), 3.15 (q, J=4.8Hz, 1H), 2.61 (s, 3H).
Embodiment 3
(R) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (3- (methylamino) pyrrolidines -1-
Base) -3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=519.4 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.52(s,1H),9.24-9.16
(m, 1H), 9.82 (dd, J=1.2,4.4Hz, 1H), 8.37 (s, 1H), 8.34 (dd, J=1.2,9.2Hz, 1H), 8.22 (d, J
=2.0Hz, 1H), 8.17 (d, J=2.4Hz, 1H), 8.03 (dd, J=2.4,8.8Hz, 1H), 7.98 (dd, J=2.0,
8.8Hz, 1H), 7.56-7.50 (m, 1H), 7.42 (d, J=9.2Hz, 1H), 3.87-3.80 (m, 1H), 3.51-3.46 (m,
1H),3.35-3.29(m,2H),3.23-3.17(m,1H),2.61(s,3H),2.60-2.57(m,3H),2.33-2.28(m,
1H),2.12-2.03(m,1H)。
Embodiment 4
N- (4- ((3S, 4S) -3- amino-4-hydroxies pyrrolidin-1-yl) -3- (trifluoromethyl) phenyl) -3- (imidazos
[1,2-b] pyridazine -3- acetenyls) -4- methyl benzamides, and N- (4- ((3R, 4R) -3- amino-4-hydroxy pyrrolidines -1-
Base) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- toluyl amine blends
LC-MS (m/z)=521.6 [M+H]+.1H NMR (400MHz, CDCl3) δ 8.61 (dd, J=1.6,4.4Hz,
1H), 8.14 (d, J=2.0Hz, 1H), 8.08 (dd, J=1.6,9.2Hz, 1H), 8.05 (s, 2H), 7.90-7.86 (m, 2H),
7.46 (s, 1H), 7.36-7.30 (m, 2H), 4.25-4.22 (m, 1H), 3.68-3.58 (m, 3H), 3.35-3.33 (m, 1H),
3.25-3.22(m,2H),3.20-3.10(m,1H),2.64(s,3H)。
Embodiment 5
(R) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (piperidines -3- bases-amino) -3- (three
Methyl fluoride) phenyl) benzamide
LC-MS (m/z)=519.4 [M+H]+.1H NMR (400MHz, CDCl3) δ 8.28 (d, J=1.2Hz, 2H),
7.74-7.72 (m, 2H), 7.62-7.60 (m, 2H), 7.32 (d, J=8.0Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 6.58
(br, 1H), 3.53-3.51 (m, 1H), 3.21 (dd, J=2.4,11.6Hz, 1H), 2.91-2.86 (m, 1H), 2.77-2.71
(m,1H),2.64-2.59(m,1H),2.48(s,3H),1.94-1.92(m,1H),1.60-1.51(m,3H)。
Embodiment 6
(R)-N- (4- (3- amino piperidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -3-
Acetenyl) -4- methyl benzamides
LC-MS (m/z)=519.4 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.59(s,1H),8.20-8.09
(m, 5H), 7.96 (d, J=7.6Hz, 1H), 7.57-7.53 (m, 2H), 7.40-7.37 (m, 2H), 3.16-3.13 (m, 2H),
2.85-2.83(m,1H),2.72-2.70(m,2H),2.60(s,3H),2.04-2.01(m,1H),1.84-1.81(m,1H),
1.64-1.56(m,1H),1.50-1.45(m,1H)。
Embodiment 7
(S)-N- (4- (3- amino piperidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -3-
Acetenyl) -4- methyl benzamides
LC-MS (m/z)=519.5 [M+H]+.1H NMR (400MHz, DMSO-d6) δ 10.57 (s, 1H), 8.74 (d, J=
7.6Hz, 1H), 8.21-8.18 (m, 2H), 8.12 (dd, J=1.6,8.8Hz, 1H), 8.03 (m, 2H), 7.96 (dd, J=1.6,
7.6Hz, 1H), 7.58 (t, J=8.8Hz, 2H), 7.41 (m, 1H), 3.23 (m, 1H), 3.15-3.12 (m, 1H), 2.86-2.83
(m,1H),2.74-2.68(m,2H),2.60(s,3H),2.03-2.00(m,1H),1.85-1.82(m,1H),1.65-1.56
(m,1H),1.48-1.41(m,1H)。
Embodiment 8
(R) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (3- (methylamino) piperidin-1-yl) -
3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=533.6 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.58(s,1H),8.75-8.71
(m, 3H), 8.21-8.19 (m, 2H), 8.12 (d, J=8.0Hz, 1H), 7.96 (d, J=8.0Hz, 1H), 7.59-7.54 (m,
2H), 7.41 (m, 1H), 3.24-3.19 (m, 2H), 2.87-2.84 (m, 1H), 2.73 (q, J=10.0Hz, 2H), 2.61 (s,
6H),2.12-2.09(m,1H),1.88-1.84(m,1H),1.65-1.55(m,1H),1.49-1.44(m,1H),1.27-1.16
(m,1H)。
Embodiment 9
N- (4- (4- amino piperidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -3- acetylene
Base) -4- methyl benzamides
LC-MS (m/z)=519.5 [M+H]+.1H NMR (400MHz, DMSO-d6) δ 10.55 (s, 1H), 8.74 (d, J=
3.6Hz, 1H), 8.20 (s, 1H), 8.17 (d, J=1.6Hz, 1H), 8.09-8.03 (m, 3H), 7.95 (d, J=8.0Hz, 1H),
7.57 (t, J=8.0Hz, 2H), 7.40 (m, 1H), 2.97-2.94 (m, 2H), 2.85-2.76 (m, 3H), 2.60 (s, 3H),
1.99-1.97(m,2H),1.72-1.64(m,2H)。
Embodiment 10
(R) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (methyl (piperidines -3- bases) amino) -
3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=533.2 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.53(s,1H),8.74(dd,J
=1.6,4.4Hz, 1H), 8.28 (dd, J=1.6,9.2Hz, 1H), 8.21 (d, J=2.0Hz, 1H), 8.17 (d, J=2.4Hz,
1H), 8.09 (dd, J=2.4,8.8Hz, 1H), 7.96 (dd, J=1.6,8.0Hz, 1H), 7.63-7.57 (m, 2H), 7.56 (d,
J=8.0Hz, 1H), 7.42 (q, J=4.4Hz, 1H), 3.02 (d, J=11.6Hz, 1H), 2.85-2.82 (m, 2H), 2.61 (s,
3H),2.56(s,3H),2.36-2.31(m,2H),1.85-1.82(m,1H),1.63-1.59(m,1H),1.24(m,2H)。
Embodiment 11
(R)-N, N- dimethyl -1- (4- nitros -2- (trifluoromethyl) phenyl) pyrrolidines -3- amine
By fluoro- 4- nitros -2- (trifluoromethyl) benzene (300mg, 1.4mmol) of 1-, (R)-(+) -3- dimethylamino pyrrolidines
Dihydrochloride (261mg, 1.4mmol) is dissolved in acetonitrile (20mL) and adds potassium carbonate (387mg, 2.8mmol) afterwards.Reaction system is 80
It is stirred overnight at DEG C, then cools down, reactant mixture is poured into water (10mL), and is extracted with ethyl acetate (3 × 20mL).Receive
Collect organic phase, Na2SO4 is dried, filtered and be concentrated to dryness.Crude title compound (320mg) is obtained to be directly used in for yellow solid
React in next step.LC-MS (m/z)=304.4 [M+H]+.
(R) -1- (4- amino -2- (trifluoromethyl) phenyl)-N, N- dimethyl pyrrolidine -3- amine
By (R)-N, N- dimethyl -1- (4- nitros -2- (trifluoromethyl) phenyl) pyrrolidines -3- amine (310mg, 1mmol)
It is dissolved in methanol (15mL) and adds Pd/C (10%, 31mg) afterwards.System vacuumizes, and is then flushed with hydrogen gas.In room under hydrogen balloon atmosphere
Temperature is stirred overnight, and mixture is filtered with diatomite, and diatomite is thoroughly washed with methanol.Gained crude product is through post layer after filtrate concentration
Analysis purifying (ethyl acetate/petroleum ether=1:1) it is yellow solid, to obtain title compound (265mg, 97%).LC-MS(m/z)
=274.2 [M+H]+.
(R)-N- (4- (3- (dimethyl amine) pyrrolidin-1-yl) -3- (trifluoromethyl) phenyl) -3- (imidazos [1,2-b]
Pyridazine -3- acetenyls) -4- methyl benzamides
Into 20mL single port bottles add 3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl benzoic acids (100mg,
0.36mmol), (R) -1- (4- amino -2- (trifluoromethyl) phenyl)-N, N- dimethyl pyrrolidine -3- amine (96mg,
0.36mmol), 1- ethyls-(3- dimethylaminopropyls) phosphinylidyne diimmonium salt hydrochlorate (140mg, 0.72mmol), 4- diformazan ammonia
Yl pyridines (88mg, 0.72mmol), N ' dinethylformamides (10mL).Mixture displacement nitrogen is heated into 50 DEG C afterwards three times to stir
Mix 3 hours, then cool down, reactant mixture is poured into water (15mL), and extracted with dichloromethane (3 × 15mL).Collection has
Machine phase, Na2SO4 are dried, are filtered and be concentrated to dryness.Crude product purifies (ethanol/methylene=1 through column chromatography:20) title, is obtained
Compound (35mg, 13%) is yellow solid.LC-MS (m/z)=533.6 [M+H]+.1H NMR(400MHz,DMSO-d6)δ
10.41 (s, 1H), 8.72 (dd, J=1.6,4.4Hz, 1H), 8.47 (s, 1H), 8.26 (dd, J=1.2,9.2Hz, 1H), 8.24
(d, J=3.2Hz, 1H), 8.21 (d, J=1.6Hz, 1H), 8.18 (d, J=2.8Hz, 1H), 7.95 (dd, J=1.6,8.0Hz,
1H), 7.53 (d, J=5.6Hz, 1H), 7.51 (d, J=6.4Hz, 1H), 7.39 (dd, J=4.4,9.2Hz, 1H), 4.02 (s,
1H), 3.43-3.34 (m, 2H), 3.28-3.23 (m, 1H), 3.14-3.08 (m, 1H), 2.83-2.81 (d, J=9.2Hz, 3H),
2.60(s,3H),2.56-2.53(m,3H),2.37-2.30(m,1H),2.18-2.13(m,1H)。
Example 1 below 2-19 is all prepared according to the method for scheme 2 and embodiment 11.
Embodiment 12
N- (4- ((3R, 4R) -3- azido -4- hydroxyl pyrrolidine -1- bases) -3- (trifluoromethyl) benzene
Base) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl benzamides, and
N- (4- ((3S, 4S) -3- azido -4- hydroxyl pyrrolidine -1- bases) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,
2-b] pyridazine -3- acetenyls) -4- toluyl amine blends
LC-MS (m/z)=547.8 [M+H]+.1H NMR (400MHz, CDCl3) δ 8.55 (d, J=2.0Hz, 1H), 8.11
(dd, J=1.2,8.8Hz, 1H), 8.07 (s, 1H), 8.06 (d, J=2.0Hz, 1H), 7.99 (s, 1H), 7.89 (dd, J=
2.0,8.8Hz, 1H), 7.82 (dd, J=2.0,8.0Hz, 2H), 7.40 (d, J=8.0Hz, 1H), 7.24-7.18 (m, 2H),
4.35-4.29 (m, 1H), 4.05-4.02 (m, 1H), 3.77 (q, J=4.4Hz, 1H), 3.60 (q, J=4.4Hz, 1H), 3.23-
3.14(m,2H),2.65(s,3H),2.05(s,1H)。
Embodiment 13
N- (4- ((3S, 4R) -3- hydroxy-4-methyls pyrrolidin-1-yl) -3- (trifluoromethyl) phenyl) -3- (imidazos
[1,2-b] pyridazine -3- acetenyls) -4- methyl benzamides, and N- (4- ((3R, 4S) -3- hydroxy-4-methyl pyrrolidines -1-
Base) -3- (trifluoromethyl) phenyl) -3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- toluyl amine blends
LC-MS (m/z)=520.4 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.32(s,1H),8.72(dd,J
=1.6,4.4Hz, 1H), 8.26 (dd, J=1.6,9.2Hz, 1H), 8.23 (s, 1H), 8.19 (d, J=2.0Hz, 1H), 8.08
(d, J=2.4Hz, 1H), 7.94 (dd, J=2.0,8.0Hz, 1H), 7.89 (dd, J=2.4,9.2Hz, 1H), 7.53 (d, J=
8.0Hz, 1H), 7.39 (dd, J=4.4,9.2Hz, 1H), 7.11 (d, J=9.2Hz, 1H), 5.07 (d, J=4.4Hz, 1H),
3.86-3.84 (m, 1H), 3.51-3.44 (m, 2H), 3.11 (dd, J=4.8,9.6Hz, 1H), 2.94 (dd, J=6.4,
9.2Hz, 1H), 2.60 (s, 3H), 2.10-2.06 (m, 1H), 1.01 (d, J=6.8Hz, 3H).
Embodiment 14
(R)-N- (4- (3- (dimethylamino) piperidin-1-yl) -3- (trifluoromethyl) phenyl) -3- (rattle away by imidazo [1,2-b]
Piperazine -3- acetenyls) -4- methyl benzamides
LC-MS (m/z)=547.6 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.58(s,1H),10.12(s,
1H), 8.73 (d, J=3.2Hz, 1H), 8.28-8.19 (m, 3H), 8.11 (d, J=8.8Hz, 1H), 7.96 (d, J=8Hz,
1H), 7.57 (d, J=8.8Hz, 1H), 7.55 (d, J=8Hz, 1H), 7.40 (m, 1H), 3.29-3.27 (m, 2H), 2.89-
2.70(m,8H),2.61(s,3H),2.16-2.13(m,1H),1.90-1.87(m,1H),1.63-1.53(m,2H),
1.24-1.21(m,1H)。
Embodiment 15
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- ((1- methyl piperidine -4- bases) amino) -3-
(trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=533.7 [M+H]+.1H NMR (400MHz, CDCl3) δ 9.02 (d, J=4.0Hz, 1H), 8.54
(s, 1H), 8.46 (d, J=9.2Hz, 2H), 8.15 (d, J=2.0Hz, 1H), 7.91 (dd, J=2.0,8.0Hz, 1H), 7.90-
7.86 (m, 2H), 7.74 (dd, J=2.4,8.0Hz, 1H), 7.46 (d, J=8.0Hz, 1H), 7.01 (d, J=9.2Hz, 1H),
3.60 (d, J=13.2Hz, 2H), 3.26-3.20 (m, 2H), 2.92 (d, J=7.6Hz, 3H), 2.63 (s, 3H), 2.31 (d, J
=14.0Hz, 2H), 2.16-2.14 (m, 1H), 1.86-1.76 (m, 2H).
Embodiment 16
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (methyl (1- methyl piperidine -4- bases) ammonia
Base) -3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=547.2 [M+H]+.1H NMR (400MHz, CD3OD) δ 8.63 (dd, J=1.6,4.4Hz,
1H), 8.17 (d, J=1.6Hz, 1H), 8.10 (dd, J=1.6,4.4Hz, 2H), 8.07 (s, 1H), 7.97 (dd, J=2.8,
8.4Hz, 1H), 7.89 (dd, J=2.0,8.0Hz, 1H), 7.54 (d, J=8.8Hz, 1H), 7.48 (d, J=8.0Hz, 1H),
7.36 (q, J=8.8Hz, 1H), 3.03 (d, J=8.4Hz, 2H), 2.72 (s, 3H), 2.65 (s, 3H), 2.41 (s, 3H),
2.34-2.28(m,3H),1.91-1.87(m,2H),1.66-1.58(m,2H)。
Embodiment 17
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (4- methyl isophthalic acids-homopiperazine
Base) -3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=533.4 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.84(s,1H),8.73(dd,J
=1.6,4.4Hz, 1H), 8.26 (dd, J=1.6,9.2Hz, 1H), 8.24 (s, 1H), 8.21 (d, J=1.6Hz, 1H), 8.18
(d, J=2.4Hz, 1H), 8.11 (dd, J=2.4,8.4Hz, 1H), 7.96 (dd, J=2.0,8.0Hz, 1H), 7.62 (d, J=
8.4Hz, 1H), 7.53 (d, J=8.4Hz, 1H), 7.40 (dd, J=4.4,9.2Hz, 1H), 3.50-3.43 (m, 3H), 3.45-
3.28(m,2H),3.20-3.09(m,3H),3.05-3.03(m,1H),2.84(s,3H),2.60(s,3H),2.14-2.09(m,
1H)。
Embodiment 18
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (((3aR, 5r, 6aS) -2- methyl octahydros
Pentamethylene [C] pyrroles -5- bases) amino) -3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=559.3 [M+H]+.1H NMR(400MHz,DMSO-d6)δ10.27(s,1H),10.04(s,
1H), 8.73 (d, J=4.4Hz, 1H), 8.28-8.26 (m, 2H), 8.18 (d, J=1.6Hz, 1H), 7.97-7.96 (m, 1H),
7.93 (dd, J=1.6,8.0Hz, 1H), 7.85 (d, J=9.2Hz, 1H), 7.52 (d, J=8.0Hz, 1H), 7.40 (dd, J=
4.4,9.2Hz,1H),7.01-6.98(m,1H),4.41(s,1H),3.83-3.75(m,2H),3.14-3.07(m,2H),2.86
(s,3H),2.60(s,3H),2.44-2.39(m,2H),2.30-2.27(m,1H),1.60-1.53(m,1H),1.42-1.34
(m,2H)。
Embodiment 19
3- (imidazo [1,2-b] pyridazine -3- acetenyls) -4- methyl-N- (4- (methyl ((3aR, 5r, 6aS) -2- methyl
Octahydro pentamethylene [C] pyrroles -5- bases) amino) -3- (trifluoromethyl) phenyl) benzamide
LC-MS (m/z)=573.6 [M+H]+.
The suppression that the compound of the present invention is bred to Bcr-Abl protein kinase activities and cell is to use journey described below
What sequence was tested.
Embodiment A:The test of Bcr-Abl protein kinase enzymatic activitys
Kinases Abl is purchased from Carna companies, and substrate A TP is purchased from Sigma companies, substrate TK substrate-biotin and inspection
Test agent box HTRF KinEASE-TK kit are purchased from Cisbio companies, from HTRF (Homogeneous Time Resolved
Fluorescence, homogeneous phase time discrimination fluorescence) method detection target compound Inhibiting enzyme activity, operating method is according to kit
Illustrate to carry out.By ATP (10mM) and (500 μM) of TK substrate-biotin with buffer solution (Hepes 50mM pH7.2,
MgCl210mM,EGTA 5mM,EDTA 2mM,MnCl2 2mM,Cisbio SEB 50nM,Na3VO4 0.1mM,BSA 0.1mg/
ML, DTT 1mM) dilute the substrate mixed solution (2.2 for being configured to ATP (13.2 μM)-TK substrate-biotin (2.2 μM)
×);Abl kinases is configured to the 2.2 of Abl (WT 1.8nM, T315I 1.1nM, E255K 0.66nM) with the dilution of above-mentioned buffer solution
× enzyme working solution is standby;
Target compound (P1-P19) and positive control drug (Ponatinib) are configured to 1.0 respectively with above-mentioned buffer solution
× 10-4mol/L, 3.3 × 10-5mol/L, 1.1 × 10-5mol/L, 3.7 × 10-6mol/L, 1.2 × 10-6mol/L, 4.1 ×
10-7mol/L, 1.4 × 10-7mol/L, 4.6 × 10-8mol/L, 1.5 × 10-8mol/L, 5.1 × 10-9mol/L concentration gradient
Sample solution (DMSO concentration be 11%), in sequentially adding 5 μ L enzyme solutions and 1 μ L sample solution per hole on 384 orifice plates;Blank
Hole adds 5 μ L buffer solutions and 1 μ L11% DMSO solution;26 DEG C are incubated 15 minutes, add 5 μ L ATP-TK substrate
Biotin substrate mixed solution initial actions;It is incubated 60 minutes at 26 DEG C;The μ L of HTRF detection reagents 10 are added, are incubated at 26 DEG C
60 minutes.Using fluorescent value of the TR-FRET modules measure of PerkinElmer multi-function microplate readers per hole, miaow of the present invention is calculated
Azoles simultaneously inhibiting rate and IC50 of [1,2-b] pyridazine amide-type Bcr-Abl inhibitor to Abl.
Embodiment B:K562 cytoactives are tested
Imidazo [1,2-b] pyridazine amide-type Bcr-Abl inhibitor pair of the present invention is examined using Cell Titer-Glo methods
The growth inhibitory activity of tumour cell:Take the logarithm the human chronic polymorpho nuclear leukemia cells (K562 cells) in growth period, with addition
The 10%FBS culture mediums of RPMI 1640 are diluted to 3 × 104/mL cell solution, parallel to be inoculated in 96 well culture plates
(3000/hole), per hole, inoculation volume is 100 μ L, 37 DEG C, overnight incubation in 5%CO2 incubators;Various concentrations are added per hole
The μ L of testing compound 5, make the final concentration of 1 × 10-7mol/L, 3.3 × 10-8mol/L, 1.1 × 10- of compound in hole
8mol/L, 3.7 × 10-9mol/L, 1.2 × 10-9mol/L, 4.1 × 10-10mol/L, 1.4 × 10-10mol/L, 4.5 × 10-
11mol/L, 1.5 × 10-11mol/L, 5.1 × 10-12mol/L, each concentration set 2 multiple holes, and negative control refinement born of the same parents are not added with
Compound, if 10 multiple holes, Ponatinib are positive control, continue to cultivate 72h;Cell Titer-Glo50 μ L are added per hole,
Vibration 10 minutes, determined per hole values of chemiluminescence, then using the chemiluminescence module of PerkinElmer multi-function microplate readers
Cell inhibitory rate is calculated, and IC50 values are obtained according to inhibiting rate.
Imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors provided by the invention to Bcr-Abl kinases and
The inhibitory activity result of K562 cells, as shown in table 1:
The inhibitor of table 1 is to Bcr-Abl kinase inhibiting activities result (IC50)
ND:Do not detect
As a result show the present invention compound imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors to Bcr-
Abl kinases and K562 cell growths have stronger inhibitory activity.Bcr-Abl kinases plays critically important in cell signalling
Effect, it is by phosphorylation and activates a series of stream substrates, promotes the unlimited hyperplasia of CML maturation granulocytes.Bcr-Abl is just
Do not expressed in normal cell, be the ideal targets for treating CML.Above-mentioned imidazo [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitions
Agent is good to the proliferation inhibiting effect of tumour cell, can be used as antineoplastic.
Claims (21)
1. compound or its pharmaceutically acceptable salt shown in formula I:
Wherein:
(a)R1It is independent hydrogen, or methyl;R2It is any substituted n membered cyclic alkyls, wherein n=3-11, and include on ring
At most n-1 hetero atom, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus, or
(b)R1And R2Connection forms a m member azepine cyclic hydrocarbon radical arbitrarily substituted, wherein m=3-11, and includes at most on ring
M-2 other hetero atoms, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
2. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2It is any substituted n membered cyclic alkyls, wherein n=3-11, and include at most n-1 hetero atom, these hetero atoms on ring
Independent is selected from nitrogen, oxygen, sulphur and phosphorus.
3. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2It is any substituted n member cycloalkyl, wherein n=3-11, and include at most n-1 hetero atom, these hetero atoms on ring
Independent is selected from nitrogen, oxygen, sulphur and phosphorus.
4. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2It is any substituted n member cycloalkyl, wherein n=6-11, and include at least one nitrogen-atoms on ring, and at most n-2
Hetero atom, these hetero atom independences are selected from nitrogen, oxygen, sulphur and phosphorus.
5. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2It is that any substituted n member azacycloalkyls, wherein n=6-11, and ring substituents are selected from methyl, halogenic substituent,
Hydroxyl and amino.
6. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2It is methyl substituted n members azacycloalkyl, wherein n=6-11.
7. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (a) R1It is independent hydrogen, Huo Zhejia
Base;R2Selected from following radicals:
8. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (b) R1And R2Connection forms one and appointed
The m member azepine cyclic hydrocarbon radicals of meaning substitution, wherein m=3-11, and include at most m-2 other hetero atoms, these miscellaneous originals on ring
Son is independent to be selected from nitrogen, oxygen, sulphur and phosphorus.
9. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (b) R1And R2Connection forms one and appointed
The m member azacycloalkyls of meaning substitution, wherein m=3-11, and include at most m-2 other hetero atoms, these miscellaneous originals on ring
Son is independent to be selected from nitrogen, oxygen, sulphur and phosphorus.
10. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (b) R1And R2Connection forms one and appointed
The m member azacycloalkyls of meaning substitution, wherein m=5-7, and include at most m-2 other hetero atoms, these hetero atoms on ring
Independent is selected from nitrogen, oxygen, sulphur and phosphorus.
11. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (b) R1And R2Connection forms one and appointed
The m member azacycloalkyls of meaning substitution, wherein m=5-7, and include 0-1 other nitrogen-atoms on ring.
12. compound as claimed in claim 1 or its pharmaceutically acceptable salt, wherein (b) R1And R2Connection forms one and appointed
Anticipate the m member azacycloalkyls of substitution, wherein m=5-7,0-1 other nitrogen-atoms are included on ring, and substituent is selected from first
Base, halogenic substituent, hydroxyl and amino.
13. compound as claimed in claim 1, described compound is selected from following structural formula:
14. compound as claimed in claim 1, described structural formula of compound such as P16:
15. compound as claimed in claim 1, described structural formula of compound such as P17:
16. compound as claimed in claim 1 or its pharmaceutically acceptable salt, described pharmaceutically acceptable salt include
But it is not limited to hydrochloride, phosphate, sulfate, acetate, trifluoroacetate, maleate, benzene sulfonate, toluene sulfonic acide
Salt, fumarate, tartrate etc..
17. a kind of Pharmaceutical composition, it includes the compound as claimed in claim 1 of unit dose, one kind can pharmaceutically connect
The carrier and excipient received, and optional other Bcr-Abl kinase activations mediation treatment for diseases agent.
18. the pro-drug of compound as claimed in claim 1.
19. compound as claimed in claim 1 or its pharmaceutically acceptable salt are preparing prevention and/or treated by Bcr-
Application in the disorder agent of Abl kinase activations mediation.
20. application as claimed in claim 19, the Bcr-Abl kinase activations mediation illness is proliferative diseases.
21. application as claimed in claim 20, the proliferative diseases are selected from:Solid tumor, sarcoma, chronic myeloid/grain
Chronic myeloid leukemia (CML, chronic myelogenous leukemia), gastrointestinal stromal tumor (GIST), acute myelogenous are white
Blood disease (ALL), thyroid cancer, stomach cancer, the carcinoma of the rectum, Huppert's disease, neoplasia and other Hypertrophic or proliferative diseases,
Or its combination.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610304561.XA CN107353286A (en) | 2016-05-10 | 2016-05-10 | Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610304561.XA CN107353286A (en) | 2016-05-10 | 2016-05-10 | Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107353286A true CN107353286A (en) | 2017-11-17 |
Family
ID=60271125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610304561.XA Pending CN107353286A (en) | 2016-05-10 | 2016-05-10 | Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107353286A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013162727A1 (en) * | 2012-04-25 | 2013-10-31 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CN104470934A (en) * | 2012-07-30 | 2015-03-25 | 爱仕达生物技术有限责任公司 | Protein kinase inhibitors |
CN106795152A (en) * | 2014-08-26 | 2017-05-31 | 安斯达尔生物技术有限责任公司 | Kinases inhibitor |
-
2016
- 2016-05-10 CN CN201610304561.XA patent/CN107353286A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013162727A1 (en) * | 2012-04-25 | 2013-10-31 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CN104470934A (en) * | 2012-07-30 | 2015-03-25 | 爱仕达生物技术有限责任公司 | Protein kinase inhibitors |
CN106795152A (en) * | 2014-08-26 | 2017-05-31 | 安斯达尔生物技术有限责任公司 | Kinases inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2833576T3 (en) | Novel glutaminase inhibitors | |
CN103097361B (en) | 1-(aryl methyl)-quinazoline-2,4-dione as parp inhibitor and its application | |
KR101475088B1 (en) | Aza-benzothiophenyl compounds and methods of use | |
CN106883213B (en) | Dual inhibitor of EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) | |
CN112955459A (en) | Bicyclic peptide ligands and uses thereof | |
EP3640248B1 (en) | Aminopyrimidine derivatives, preparation method therefor and use thereof | |
CN107840842A (en) | Alkynes is for heterocyclic compound, its preparation method and its in application pharmaceutically | |
WO2008150118A2 (en) | Novel amide derivative for inhibiting the growth of cancer cells | |
CN101903387A (en) | 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents | |
CA3004372A1 (en) | Pyrimidine derivative and use thereof | |
JP2022525069A (en) | RAD51 inhibitor | |
CN107619388A (en) | Heterocyclic compound as FGFR inhibitor | |
AU2013326850B2 (en) | Novel compounds, their preparation and their uses | |
TW202003496A (en) | Novel phosphoinositide 3-kinase inhibitor and preparation method and use thereof | |
CN115073469A (en) | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | |
CN112313207B (en) | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | |
TW200813080A (en) | Process and intermediate | |
CN101973989B (en) | Thiazole amide compound and medicinal application thereof for treating malignancy | |
ES2562903T3 (en) | New compound that has PARP inhibitory activity | |
CN109422760B (en) | FGFR4 inhibitor and application thereof | |
CN104804001B9 (en) | 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof | |
CN113966331B (en) | Triaryl ring compound containing urea structure and application thereof | |
CN107353286A (en) | Novel imidazole simultaneously [1,2-b] pyridazine amide-type Bcr-Abl kinase inhibitors and its preparation method and application | |
CN115490671A (en) | PARP7 inhibitors and process for preparing the same | |
CN105541792B (en) | Polycyclic class PI3K inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171117 |